Niraparib as First-Line Maintenance Therapy in Patients with Stage III Ovarian Cancer and No Visible Residual Disease: AR1ZE Real-World Study

Niraparib as First-Line Maintenance Therapy in Patients with Stage III Ovarian Cancer and No Visible Residual Disease: AR1ZE Real-World Study

Abstract Introduction Niraparib was approved for first-line (1L) maintenance (1LM) treatment of patients with advanced epithelial ovarian cancer (EOC) following the PRIMA/ENGOT-OV26/GOG-3012 (PRIMA) trial. PRIMA was restricted to patients at higher risk of progression (excluded stage III EOC with no...

Full description

Saved in:
Bibliographic Details
Main Authors: Dana M. Chase, Maya Hanna, Jonathan T. Lim, Tirza Areli Calderón Boyle, Mark Guinter, Madeline Richey, Khilna Patel, Jeanne M. Schilder, Jean A. Hurteau, Amanda K. Golembesky
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-01-01
Series:Oncology and Therapy
Subjects:
Electronic health records
First-line maintenance therapy
Niraparib
Ovarian cancer
Real-world
Time to next treatment
Online Access:https://doi.org/10.1007/s40487-024-00318-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40487-024-00318-y

Similar Items